The second national anti‐tuberculosis drug resistance survey in Tanzania, 2017–2018

OBJECTIVE: To determine the levels and patterns of resistance to first‐ and second‐line anti‐tuberculosis (TB) drugs among new and previously treated sputum smear positive pulmonary TB (PTB) patients. METHODS: We conducted a nationally representative cross‐sectional facility‐based survey in June 2017–July 2018 involving 45 clusters selected based on probability proportional to size. The survey aimed to determine the prevalence of anti‐TB drug resistance and associated risk factors among smear positive PTB patients in Tanzania. Sputum samples were examined using smear microscopy, Xpert MTB/RIF, culture and drug susceptibility testing (DST). Logistic regression was used to account for missing data and sampling design effects on the estimates and their standard errors. RESULTS: We enrolled 1557 TB patients, including 1408 (90.4%) newly diagnosed and 149 (9.6%) previously treated patients. The prevalence of multidrug‐resistant TB (MDR‐TB) was 0.85% [95% confidence interval (CI): 0.4–1.3] among new cases and 4.6% (95% CI: 1.1–8.2) among previously treated cases. The prevalence of Mycobacterium tuberculosis strains resistant to any of the four first‐line anti‐TB drugs (isoniazid, rifampicin, streptomycin and ethambutol) was 1.7% among new TB patients and 6.5% among those previously treated. Drug resistance to all first‐line drugs was similar (0.1%) in new and previously treated patients. None of the isolates displayed poly‐resistance or extensively drug‐resistant TB (XDR‐TB). The only risk factor for MDR‐TB was history of previous TB treatment (odds ratio = 5.7, 95% CI: 1.9–17.2). CONCLUSION: The burden of MDR‐TB in the country was relatively low with no evidence of XDR‐TB. Given the overall small number of MDR‐TB cases in this survey, it will be beneficial focusing efforts on intensified case detection including universal DST.